Overview
SNDX market data
Price History
SNDX price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$3.29 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.39 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $9.49 – $25.59 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $1.7K · P/B 28.25 · P/S 7.85.
Company News
HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $40 Price TargetBenzinga · Jul 15, 2026, 10:29 AM
8-K filing — Syndax Pharmaceuticals Inc (SNDX)SEC EDGAR · Jul 14, 2026, 12:30 PM
Syndax Presents Key Revuforj Data In Multiple Acute Leukemia Subtypes And Settings At EHA 2026 CongressBenzinga · Jun 11, 2026, 11:11 AM
Syndax Announces Publication Of Phase 1/2 SAVE Trial Data Of All-Oral Regimen Of Revuforj, Decitabine/Cedazuridine, And Venetoclax In R/R NPM1m, KMT2Ar, or NUP98r AML In Journal Of Clinical OncologyBenzinga · Jun 11, 2026, 11:09 AM
Syndax Pharma Enters Into Privately Negotiated Subscription Agreements For Issuance Of $250M Aggregate Principal Amount Of 2.25% Convertible Senior Notes Due 2031Benzinga · Jun 4, 2026, 11:20 AM
Syndax Pharmaceuticals Presents Data Showing Revuforj Achieved 90% Two-Year Overall Survival Post-Transplant In Acute Leukemia Patients, With Favorable Pharmacokinetic Profile Supporting Flexible Administration At ASCO 2026Benzinga · Jun 2, 2026, 8:03 PM
Syndax to Host R&D Day On July 14 Highlight Late-Stage Revumenib And Axatilimab Programs, Including Ongoing Trials In Idiopathic Pulmonary Fibrosis, Newly Diagnosed Chronic Graft-Versus-Host Disease, And Newly Diagnosed Acute LeukemiaBenzinga · Jun 1, 2026, 11:11 AM
Syndax To Present Data Showing Favorable Post-Transplant Outcomes With Revumenib In Acute Leukemia And Highlight Ongoing Pivotal Trials At ASCO 2026Benzinga · May 21, 2026, 9:10 PM
Syndax Announces Participation in Upcoming Investor ConferencesGlobenewswire Inc · May 20, 2026, 11:15 AM